Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models

Ayan Deya, T.M. Chozhavel Rajanathana, Harish Chandra, Hari P.R. Pericherla, Sanjeev Kumar, Huzaifa S. Choonia, Mayank Bajpai, Arun K. Singh, Anuradha Sinha, Gurwinder Saini, Parth Dalal, Sarosh Vandriwal, Mohammed A. Raheem, Rupesh D. Dive, Neelam L. Navlani, Vibhuti Sharma, Aashini Parikh, Siva Prasatha, M. Sankar Rao, Kapil Maithal.

Vaccine Technology Centre, Cadila Healthcare Ltd, Ahmedabad, India
Zydus Research Centre, Cadila Healthcare Ltd, Ahmedabad, India

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), initially originated in China in year 2019 and spread rapidly across the globe within 5 months, causing over 96 million cases of infection and over 2 million deaths. Huge efforts were undertaken to bring the COVID-19 vaccines in clinical development, so that it can be made available at the earliest, if found to be efficacious in the trials. We developed a candidate vaccine ZyCoV-D comprising of a DNA plasmid vector carrying the gene encoding the spike protein (S) of the SARS-CoV-2 virus. The S protein of the virus includes the receptor binding domain (RBD), responsible for binding to the human angiotensin converting enzyme (ACE-2) receptor. The DNA plasmid construct was transformed into E. coli cells for large scale production. The immunogenicity potential of the plasmid DNA has been evaluated in mice, guinea pig, and rabbit models by intradermal route at 25, 100 and 500 mg dose. Based on the animal studies proof-of-concept has been established and preclinical toxicology (PCT) studies were conducted in rat and rabbit model. Preliminary animal study demonstrates that the candidate DNA vaccine induces antibody response including neutralizing antibodies against SARS-CoV-2 and also elicited Th-1 response as evidenced by elevated IFN-γ levels.

1. Introduction

Three highly pathogenic human coronaviruses (CoVs) have been identified so far, including Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Among them, SARS-CoV was first reported in Guangdong, China in 2002 [1]. SARS-CoV caused human-to-human transmission and resulted in the 2003 outbreak with about 10% case fatality rate (CFR), while MERS-CoV was reported in Saudi Arabia in June 2012 [2]. Even though with its limited human-to-human transmission, MERS-CoV showed a CFR of about 34.0% [3]. The SARS-CoV-2 was first reported in Wuhan, China in December 2019 from patients with pneumonia, and it has exceeded both SARS-CoV and MERS-CoV in its rate of transmission among humans [4,5]. The outbreak of a novel coronavirus (SARS-CoV-2) represents a pandemic threat that has been declared a public health emergency of international concern (PHEIC). Currently, the intermediate host of SARS-CoV-2 is still unknown, and no effective prophylactics or therapeutics are available, though various drugs have shown mild to moderate protection but none of them have shown conclusive evidence.

Several pre-clinical or clinical trials are going on, which include repurposing of already approved drugs but with different indications such as anti-malarial, anti-viral, anti-parasitic drugs, or monoclonal antibodies, etc [6,7]. However, these drugs may help to prevent worsening of the coronavirus infection only and there is still an unmet need of a vaccine against novel coronavirus SARS-CoV-2.

Huge progresses were made in last one year for bringing effective vaccines against SARS-CoV-2. As per WHO draft landscape of vaccines, currently 172 vaccine candidates are in pre-clinical development, 63 are in clinical development. Among the candidates in clinical development, 6 are based on plasmid DNA technology including our vaccine candidate. Other 5 candidates are from Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/
The spike proteins of SARS-CoV-2 and SARS-CoV were reported to have identical 3-D structures in the receptor-binding domain. SARS-CoV spike protein has a strong binding affinity to human Angiotensin converting enzyme 2 (ACE-2) receptor, based on biochemical interaction studies and crystal structure analysis. SARS-CoV-2 and SARS-CoV spike proteins have high degree of homology and they share more than 70% identity in amino acid sequences [17]. Further, Wan et al., reported that glutamine residue at position 394 (E394) in the SARS-CoV-2 receptor-binding domain (RBD), corresponding to E479 in SARS-CoV, which is recognized by the critical lysine residue at pos-31 (K31) on the human ACE-2 receptor. Further analysis suggests that SARS-CoV-2 recognizes human ACE-2 receptor more efficiently than SARS-CoV increasing the ability of SARS-CoV-2 to transmit from person to person [18]. Thus, the SARS-CoV-2 spike protein was predicted to also have a strong binding affinity to human ACE-2 receptor.

ACE-2 is demonstrated as a functional SARS-CoV-2 spike (S) protein receptor in-vitro and in-vivo. It is required for host cell entry and subsequent viral replication. Zhou et al., demonstrated that overexpressing ACE-2 receptor from different species in Hela cells with human ACE-2, pig ACE-2, and civet ACE-2 receptor allowed SARS-CoV-2 infection and replication, thereby establishing that SARS-CoV-2 uses ACE-2 as a cellular entry receptor. In transgenic mice model with overexpression of human ACE-2 receptor, SARS-CoV infection enhanced disease severity and lung injury, demonstrating that viral entry into cells through ACE-2 receptor is a critical step [19,20]. Thus for SARS-CoV-2 pathogenesis, spike (S) protein play a critical role by mediating entry of virus into the cell through human ACE-2 receptor and is an important target for vaccine development.

Here we report, design, production and pre-clinical testing of our DNA vaccine candidate. The proposed Coronavirus vaccine candidate comprises of a DNA plasmid Vector carrying spike (S) gene region of SARS-CoV-2 spike (S) protein along with gene coding for IgE signal peptide. The spike gene region was selected from submitted Wuhan Hu-1 isolate sequence (Genebank Accession No. MN908947.3). It’s expected that the plasmid construct with desired gene of interest will enter host cells, where it remains in the nucleus as an episome; without getting integrated into the host cell DNA. Thus using the host cell’s protein translation machinery, the inserted cloned DNA in the episome will direct the synthesis of the antigen it encodes. The approach involving the synthesis of antigen within the cells has several potential advantages. The protein produced by plasmid-transfected cells is likely to be expressed within the cell and folded in its native conformation. Further the signal peptide will prompt cells to translocate the protein, usually to the cellular membrane. The antigen is recognized by antigen presenting cells (APCs) and further induces antibodies including neutralizing antibodies through major histocompatibility complex (MHC) class pathway [13]. The DNA vaccine candidate induces antibody response against SARS-CoV-2 spike (S) protein, following immunization with just a single dose. Neutralizing antibody response was also demonstrated against wild type SARS-CoV-2 strain, which may play a substantial role in viral clearance and mitigation of human clinical disease. Immunogenicity of this DNA vaccine candidate targeting the SARS-CoV-2 S protein in animal model supports further clinical development of this candidate in response to the current COVID-19 pandemic situation.

2. Material and methods

2.1. Selection of spike (S) gene region based on in-silico analysis

For our DNA vaccine candidate, the target antigen amino acid sequence of SARS-CoV-2 spike(S) from Wuhan Hu-1 isolate (Gene-
bank Accession No. MN908947.3 was analysed in-silico by National Centre for Biotechnology Information (NCBI) blast tool and Clustal W multiple sequence alignment software to predict homology to other circulating SARS-CoV-2 spike(S) protein. In order to develop a vaccine candidate which provides broad protection against all circulating strains of SARS-CoV-2, the whole spike region of Wuhan Hu-1 strain having some conserved region and induce robust immune response is selected for clone development.

2.2. Generation of ZyCoV-D vaccine construct

Gene sequence was submitted to GeneArt, Thermo Fisher Scientific and codon optimized full length Spike (S) region of SARS-CoV-2 virus with IgE signal sequence was synthesized. The chemically synthesized Spike (S) gene region preceded by IgE signal sequence was inserted into pVAX-1 plasmid DNA vaccine vector (Thermo Fisher Scientific). Subsequently, the plasmid DNA construct was transformed in DH5-α chemically competent cells (Thermo Fisher Scientific). After heat shock transformation step, E. coli clones carrying the plasmid DNA constructs were isolated by plating on LB agar plate containing Kanamycin antibiotic.

Single colonies were picked and inoculated in flasks containing LB broth from Hi-Media with Kanamycin. Flasks were incubated in 37°C incubator shaker at 225 rpm for 20 Hrs. Culture from each clone was used for plasmid isolation using miniprep plasmid isolation kit. Restriction digestion was carried out with BamHI, NheI and ApaI for all constructs to check expected band releases of inserts to select the positive clones. Positive clones were selected for preparation of glycerol stocks and stored at −70°C.

2.3. In-vitro expression analysis of the constructs

In-vitro expression of DNA vaccine candidate was checked by transfection of the same in Vero cell line. For transfection experiments, Vero cells were seeded at density of 3 × 10^5 cells/ml in 6 well plates and kept in CO2 incubator to attain 80–90% confluency. After 24Hrs, once the cells reached the desired confluency, transfection was carried out in OptiMEM serum free medium with Lipofectamine 2000 reagent (Thermo Fisher). Two different concentrations (4 µg and 8 µg) of DNA construct was used for transfection experiments. We keep the amount of transfection reagent constant while plasmid DNA concentration varied to achieve 1:1 and 1:2 ratios of volume to mass. After transfection, media was replenished with fresh DMEM media (Biowest) containing 2% FBS. After 72Hrs, plates were fixed with 1:1 acetone and media was replenished with fresh DMEM media to achieve 1:1 and 1:2 ratios of volume to mass. After transfection, cells were examined by inverted microscope (Zeiss AX10) at 20X magnification.

2.4. Animal immunization

The immunogenicity study for the ZyCoV-D vaccine was carried out in inbred BALB/C mouse, guinea pig, and New Zealand white rabbit model after having ethical approval from Institutional Animal Ethics Committee, CPCSEA Reg. No.: 335/PO/RcBl/S/01/ CPCSEA, with IAEC approved application numbers: VAC/010/2020 and VAC/013/2020. BALB/c mouse (five to seven-week-old), guinea pigs (five to seven-week-old) and New Zealand White rabbits (six to twelve-week-old) were used in this study. For mouse intradermal immunization, on day 0; 25 and 100 µg of DNA vaccine was administered to the skin by using 31 gauge needle. Animals injected with empty plasmid served as vehicle control. Two weeks after immunization, animals were given first booster dose. Similarly all mice were given second booster dose two weeks after first booster dose. For guinea pig study, intradermal immunization was carried out using same dosing and schedule. In rabbits, DNA vaccine was administered to the skin by using Pharmajet® Tropis® needle free injection system (NFIS) at 500 µg dose at same 3 dose regimen and schedule. The Pharmajet® Tropis® delivers vaccines intradermally by means of a narrow, precise fluid stream that delivers the vaccine into the skin.

Blood was collected from animals on day 0 (before immunization) & 28 (after 2 dose) and on day 42 (after 3 dose) for immunological assessments from sera samples. In mouse model long term immunogenicity of the vaccine was assessed for up to day 126. Further, IFN-γ response from splenocytes at day 0, 28, and 42 were assessed.

2.5. Measurement of antibody titres by ELISA

ELISA was performed to determine antibody titres in different animal sera samples. In brief, Maxisorp ELISA plates (Nunc) were coated with 50 ng/well of recombinant S1 spike protein of SARS-CoV-2 (Acco, USA Cat no. S1N-C52H3) in phosphate-buffered saline (PBS) overnight at 4°C. Plates were washed three times with PBS then blocked with 5% skimmed milk (BD Difco) in PBS for 1 Hr at 37°C. After blocking plates were then washed thrice with PBS and incubated with serial dilutions of mouse, guinea pig and rabbit sera and incubated for 2 Hrs at 37°C. After that, plates were again washed thrice followed by incubation with 1:5,000 dilution of horse radish peroxidase (HRP) conjugated anti-guinea pig IgG secondary antibody (Sigma-Aldrich) or 1:2,000 dilution of HRP conjugated anti-mouse IgG secondary antibody (Sigma-Aldrich) or 1:5,000 dilution of HRP conjugated anti rabbit IgG secondary antibody (Sigma-Aldrich) for 1 Hr at 37°C. Plates were washed again thrice with PBS and then developed using TMB Peroxidase Substrate (KPL),Reaction was stopped with Stop Solution (1 N H2SO4). Plates were read at 450 nm wavelength within 30 min using a multimode reader (Molecular Devices, USA).

2.6. Virus neutralization assays using wildtype SARS-CoV-2

Micro-neutralization test (MNT) was performed at Translational Health Science and Technology Institute (THSTI), NCR Biotech Science Cluster, Faridabad – 121001 Haryana, India. The virus was obtained from the BEI resources, USA (Isolate USA-WA1/2020), passaged and titrated in Vero-E6 cells. The sera samples collected from immunized animals were heat-inactivated at 56°C for 30 min followed by ten fold serial dilution with cell culture medium. The diluted sera samples were mixed with a virus suspension of 100 TCID50 in 96-well plates at a ratio of 1:1 followed by 1 Hr incubation. This is followed by 1 Hr adsorption on Vero-E6 cells seeded 24 Hrs prior to experiment in 96 well tissue culture plate (1 X 10^4 cells/well in 150 µl of DMEM + 10% FBS). The cells were subsequently washed with 150 µl of serum free media and 150 µl of DMEM media supplemented with 2% FBS, followed by incubation for 3–5 days at 37°C in a 5% CO2 incubator. Cytopathic effect (CPE) was recorded under microscopes in each well. Neutralization was defined as absence of CPE compared to virus controls. Reporting for the virus neutralization titres was done as dilution factor of serum sample at which no cytopathic effect (CPE) was observed.

2.7. Detection of neutralizing antibodies by competitive inhibition ELISA

Competitive inhibition ELISA was performed using SARS-CoV-2 neutralization antibody detection kit (GenScript, USA). The kit detects circulating neutralizing antibodies against SARS-CoV-2 that
block the interaction between the receptor binding domains of the viral spike glycoprotein (RBD) with the ACE-2 cell surface receptor.

Different animal sera samples serially diluted with dilution buffer provided in the kit. The diluted sera samples were incubated with HRP conjugated RBD at 1:1 ratio for 30 min at 37 °C along with positive and negative controls. The sera and HRP conjugated RBD mix was then added to the ELISA plate pre-coated with the ACE-2 protein. After that, plates were incubated for 15 min at 37 °C followed by washing four times with wash solution provided in the kit. After washing steps, TMB solution was added to the well and incubated in dark for 15 min at room temperature, followed by addition of stop solution. Plates were read at 450 nm. Inhibition concentration (IC50) of sera sample was calculated by plotting the percentage competition value obtained for each dilution verses serum dilution in a non-linear regression curve fit using Graph pad Prism 8.0.1 software.

2.8. IFN-γ ELISPOT assay

For IFN-γ ELISPOT assay, spleens from immunized mice were collected in sterile tubes containing RPMI-1640 (Thermo Fisher Scientific) media supplemented with 2X Antibiotic-Antimycotic (Thermo Fisher Scientific). Cell suspensions were prepared by crushing the spleen with disk bottom of the plunger of 10 ml syringe (BD) in sterile petri plates. Then 5–10 ml of RPMI-1640 medium supplemented with 1X Antibiotic-Antimycotic was added to it and the contents were mixed for homogeneity. Dishes were kept undisturbed for 2 min and the clear supernatant was pipetted out slowly into cell strainer (BD). The filtrate was collected in sterile tubes and the cells were pelleted by centrifugation at 4 °C for 10 min at 250 × g in a centrifuge (Thermo Fisher Scientific). The pellet containing red blood cells (RBCs) and splenocytes were collected. 2–3 ml RBC Lysing Buffer (Invitrogen) was added to the pellet containing splenocytes and incubated at room temperature for 5–7 min. After incubation RPMI1640 supplemented with 10% FBS (Biowest) and 1X Antibiotic-Antimycotic solution was added thrice by washing steps, TMB solution was added to the well and incubated in dark for 15 min at room temperature, followed by addition of stop solution. Plates were read at 450 nm. Inhibition concentration (IC50) of sera sample was calculated by plotting the percentage competition value obtained for each dilution verses serum dilution in a non-linear regression curve fit using Graph pad Prism 8.0.1 software.

2.10. Statistical analysis

Statistical analysis of the results and graph creation were done with the Graph Pad Prism (version 8.0.1) and Microsoft Excel (version 7.0) for general statistical calculations, such as arithmetic mean and standard deviation. p values of < 0.05 were considered significant.

3. Results

3.1. In-silico analysis of SARS-CoV-2 spike (S) protein

*In-silico* analysis confirmed more than 99% homology of the spike protein amino acid sequence from Wuhan strain with other circulating strains around the world including India. Although cross-neutralization studies against different circulating strains would be needed to evaluate broader protective ability of the vaccine candidate.

3.2. Generation of DNA vaccine constructs

Synthesis of SARS-CoV-2 spike (S) protein gene containing IgE signal peptide gene region and further cloning into pVAX-1 vector results in generation of SARS-CoV-2 DNA vaccine construct. Restriction digestion with BamHI resulting in linearized DNA fragments of ~6.78 kb and restriction digestion analysis with NheI and Apal resulting in generation of fragments of ~2.89 kb of vector and ~3.89 kb of spike protein (S) gene was used to confirm the insertion of spike (S) into the vector as shown in the Figs. 1A and 1B. Gene sequencing analysis further confirmed the insertion of appropriate sequence in the desired orientation.

3.3. In-vitro expression of DNA vaccine candidate

In Immunofluorescent studies were carried out to confirm the expression of S protein on candidate DNA vaccine transfected Vero cells (Fig. 2A and 2B). Immunostaining with FITC-labeled secondary antibody revealed the expression of the Spike protein after transfection of Vero cells with the candidate vaccine constructs. Further cell nuclei were observed by DAPI counter staining.

3.4. Humoral immune response to DNA vaccine candidate

Immunization with DNA vaccine candidate by intradermal route elicited significant serum IgG responses against the S protein.
in doses-dependent manner in BALB/c mice, guinea pigs and rabbits with mean end point titres reaching ~28000 in BALB/C mice, ~140000 in guinea pigs and ~17000 in rabbits respectively on day 42 after 3 doses (Figs. 3, 4 and Fig. 5). Long term antibody response was studied in mice almost 3.5 months after the last dose and a mean end point IgG titres of ~18000 was detected (Fig. 3) suggesting sustainable immune response was generated by DNA vaccine candidate.

Neutralizing antibody titres were evaluated in BALB/C mice, guinea pigs and rabbits following immunization by using micro-neutralization assay and GenScript neutralizing antibody detection kit. Neutralizing antibodies were elicited by DNA vaccine candidate in mice, guinea pigs and rabbits. Sera from DNA vaccine candidate immunized BALB/c mice could neutralize wild SARS-CoV-2 virus strains with average MNT titres of 40 and 160 at day 42 with 25 and 100 µg dose regimens respectively (Table 1). Using GenScript neutralizing antibody detection kit average IC50 titres of 82 and 168 were obtained at day 42 with 25 and 100 µg dose regimens respectively. Further, neutralizing antibodies were also detected in long term immunogenicity studies in BALB/c mice. Significant rise in neutralizing antibodies levels were also observed in guinea pigs and rabbits (Table 1).

3.5. Cellular immune response to DNA vaccine candidate

T cell response against SARS-CoV-2 spike antigen was studied by IFN-γ ELISpot assay. Groups of BALB/c mice were sacrificed at day 14, 28, 42 post-DNA vaccine administration (25 and 100 µg dose). Splenocytes were harvested, and a single-cell suspension was stimulated for 24 h with the peptide pool covering the entire Spike glycoprotein region (10-15mers with 11 aa overlap). Significant increase in IFN-γ expression, indicative of a strong Th1 response, of 200–300 SFC per 10⁶ splenocytes against SARS-CoV-2 spike peptide pool was observed for both the 25 and 100 µg dose in post 42 day immunized mice splenocytes (Fig. 6).

3.6. Bio-distribution

Biodistribution of DNA vaccine candidate was evaluated in Wistar Rats at single dose of 0.5 mg and 1.0 mg administered intradermally. DNA was extracted from various tissue samples including the site of injection, brain, blood, lungs, intestine, kidney, heart and spleen at different time points post injection as described above. RT-PCR was performed by plasmid specific primers to detect copy numbers. Following injection of maximum ~10¹⁴ plasmid DNA copies in Wistar Rats, maximum local concentration of 10³–10⁷ plasmid copies at the site of injection were detected two hours post injection. (Figs. 7A and 7B). We also observed biodistribution of plasmid molecule in blood, lungs, intestine, kidney, heart, spleen, skin post 24 Hrs of injection which got cleared by 336 Hrs (day 14) in most of the organs except skin (site of injection) where only 10²-10³ copies were detected. Although by 672 Hrs (day 28) post injection, no plasmid copies were detected at site of injection as well.
Fig. 2. A and B. Analysis of in-vitro expression of Spike protein after transfection of Vero cells with DNA construct or empty plasmid (Control) by immunofluorescence. Expression of Spike protein was measured with polyclonal rabbit anti-SARS Spike Protein IgG and FITC anti-IgG secondary (green) and cell nuclei was observed by DAPI counter staining (blue). Images were captured using inverted fluorescence microscope at 20X Magnification.

Fig. 2 (continued)

Fig. 3. Antibody response after DNA vaccination in BALB/c mice and long term immunogenicity. BALB/c mice were immunized at week 0, 2 and 4 with DNA vaccine construct or empty control vector as described in the methods. Sera were collected at day 28 (black), day 42 (grey) and day 126 (dark grey) evaluated for SARS-CoV-2 S1-specific IgG antibodies. Antibody response were presented as end point titre and calculated considering day 0 optical density (OD) value of ELISA as end point. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Fig. 4. Antibody response after DNA vaccination in Guinea Pigs. Guinea pigs were immunized at week 0, 2 and 4 with DNA vaccine construct or empty control vector as described in the methods. Sera were collected at day 28 (checks) and day 42 (stripes) and evaluated for SARS-CoV-2 S1-specific IgG antibodies. Antibody response were presented as end point titre and calculated considering day 0 optical density (OD) value of ELISA as end point. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
induced by this construct can bind their target antigen. Further, the positive signal was not detected in cells transfected with control vector. This demonstrates the ability of the ZyCoV-D to induce robust secondary anamnestic immune response upon re-exposure, generated by balanced memory B and helper T cell expression and has been reported for other DNA vaccine candidates [22].

We also observed that ZyCoV-D vaccine is capable of inducing T-cell response complementary to antibody response in mice model as demonstrated by IFN-γ ELISPOT. This is very important as successful DNA vaccination is known to induce both humoral and cellular responses in both animals and humans [14,15,16,23]. The mechanism of action for DNA vaccine candidate includes both class-I antigen-processing pathways (i.e., intracellular processing of viral proteins and subsequent loading onto MHC class-I molecules) and class-II antigen-processing pathways (i.e., endosomal loading of peptides generated from endocytosed viral antigens).
secreted from cells using IgE signal peptide onto MHC class II molecules). Among T cell responses, Th1 response is important because vaccine-associated enhanced respiratory disease (VAERD) is associated with Th2-biased immune response. Indeed, immunopathologic complications characterized by Th2-biased immune responses have been reported in animal models of the SARS-CoV or MERS-CoV challenge [24,25,26] and similar phenomena have been reported in clinic trials vaccinated with whole-inactivated virus vaccines against RSV and measles virus [27,28]. In addition, the importance of Th1 cell responses has been highlighted by recent study of asymptomatic and mild SARS-CoV-2 convalescent samples [29]. These results collectively suggest that vaccines capable of generating balanced antibody responses and Th1 cell responses may be important in providing protection against SARS-CoV-2 diseases.

The usefulness and efficiency of a spring-powered, needle-free Injection System (NFIS) for delivering ZyCoV-D vaccine in rabbits was also demonstrated in the study. Similar observation was reported earlier with application of NFIS for DNA vaccines against Hantavirus and Zika virus [30,31]. The use of NFIS eliminates use of needles during vaccine administration thus eliminates the costs and risk associated with sharp-needle waste. Further, NFIS doesn’t require external energy sources such as gas cartridges or electricity and spring provides the power for the device. These injector create a stream of pressurized fluid that penetrates up to 2 mm in skin at high velocity resulting in uniform dispersion and higher uptake of DNA molecules in cells compare to needle and syringe where the intradermal accumulation is inconsistent across individuals (as measured by bleb size) and varies among animal species [30].

We have also demonstrated the protective efficacy of our vaccine candidate delivered by NFIS in Rhesus macaques and manuscript was available online at BioRixiv [32]. The ZyCoV-D vaccine candidate injected at dose of 2 mg by NFIS elicited significant SARS CoV-2 specific IgG, Nab titers and lower viral loads in animals post challenge.

Bio-distribution pattern for ZyCoV-D was also evaluated and level of plasmid DNA was measured at different intervals in various tissues in Wistar rats post intradermal injection. Post intradermal injection, the plasmid was found to clear off from most of the organs by 14 days post injection except site of injection, which also cleared off by 28 days post injection. Our outcome was very similar to other DNA vaccine candidate including HIV-1, Ebola, Severe Acute Respiratory Syndrome (SARS), and a West Nile Virus candidate developed [33]. Biodistribution and plasmid copy number detection studies for the vaccine candidates were done in different animal models [33]. It was observed that animals injected with 2 mg (equivalent to 10^{14} plasmid copies) by both intramuscular and subcutaneous route have detectable plasmid copies in first one week of vaccination at the site of injection with copies in order of 10^{4}-10^{6}. Over the period of 2 months, the plasmid clears from the site of injection with only a small percentage of animals in group (generally 10–20%) retaining few copies (around 100 copies) at the injection site. Directly after injection into skin or muscle, low levels of plasmids are transported via the blood stream and detected in various organs at early time points. However, the plasmids are eventually, cleared from the organs and are normally found exclusively at the site of injection at later time points.

In summary, these initial results demonstrate the immunogenicity of our ZyCoV-D DNA vaccine candidate in multiple animal models. These studies strongly support the clinical evaluation as a vaccine candidate for COVID-19 infection.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements

Authors acknowledge the support from Pharmajet, Inc, Golden, CO, USA for providing us Pharmajet® Tropis® Needle-Free Injection System (NFIS) for vaccine delivery.

Funding

Development of ZyCoV-D was supported by a grant-in-aid from Covid-19 Consortium under National Biopharma Mission, Department of Biotechnology, Government of India, to Cadila Healthcare Ltd. (Grant no. BT/COVID0003/01/20).

Authors Contribution

KM conceptualized, designed, developed the vaccine candidate, provided guidance on data analysis and manuscript preparation. AD designed, developed vaccine candidate, performed data analysis for ELISpot assay and prepare manuscript. CRM and HC developed analytical procedures for testing of the vaccine and performed data analysis for ELISA, neutralization and biodistribution assay. HPRP, HSC, GS, PD, SV, SP, SR developed process for vaccine production, MB performed animal experiments, AS performed ELISpot assay, NL and MAR performed ELISA assay, RDD performed biodistribution assay, SK, AS, VS and AP helped in construct design.

References

[1] Chan-Yang M and Rui-Heng X. “SARS: epidemiology.” Respiratory (Carlton, Vic.) vol. 8, Suppl 1 (2003).
[2] Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. The New England journal of medicine 2012;367(19):1814–20.
[3] https://www.who.int/csr/don/31-january-2020-ls-unitar-emirates/en/ “Middle East respiratory syndrome coronavirus (MERS-CoV) – United Arab Emirates”. World Health Organization. 31 January 2020.
[4] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Eng J Med 2020;382:727–33.
[5] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–9.
[6] WHO Solidarity Trial Consortium, Pan H, Petro, R, Hema-Restrepo, AM, Precioso, MP, Sathiyamoorthy, V, et al. Repurposed Antiviral Drugs for Covid-19. Interim WHO Solidarity Trial Results. N Engl J Med 2020;384(6):497–511.
[7] Marovich M, Mascola JR, Cohen MS. Monoclonal Antibodies for Prevention and Treatment of COVID-19. JAMA 2020;324(2):131–2.
[8] Draft landscape of COVID-19 candidate vaccines; https://www.who.int/csr/don/23-february-2021-covid-19-candidate-vaccines/2021
[9] Polack FP, Thomas SJ, Kitchin N, Altmann A, Dwyer Jr., et al. Safety and Efficacy of the mRNA-1273 COVID-19 Vaccine in Older Adults: The EnCoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99–111.
[10] Liang WM, Orellana KH, Dukic BV, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99–111.
[11] Liu MA, D.N.A.vaccines a review. Journal of internal medicine 2003;253(4):402–10.
[12] Klimman DM, Yamschukov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997;158(8):3635–9.
[13] Kutzler MA, Weiner DB. DNA vaccines: ready for prime time?. Nat Rev Genet 2008;9(10):776–88.
[14] Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 2019;19(9):1013–22.
[15] Martin JE, Louder MK, Holman LA, Gordon J, Enama ME, Larkin BD, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008;26(50):6338–43.
[16] Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. E. Clinical Medicine 2020; https://doi.org/10.1016/j.eclinm.2020.100985.
[17] Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences 2020;63 (3):457–60.
[18] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 2020;94(7). https://doi.org/10.1128/JVI.00127-20.
[19] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
[20] Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46(4):586–90.
[21] Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DP, Dugun DP, et al. In vivo electroproporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011;6(5). https://doi.org/10.1371/journal.pone.0019252.
[22] Konishi E, Yamane M, Kurane I, Mason, PWM, Japanese encephalitis DNA vaccine candidates expressing pre-membrane and envelope genes induce virus--specific memory B cells and long-lasting antibodies in swine. Virology 2000;268(1):49–55.
[23] Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 2020;11(6201). https://doi.org/10.1038/s41467-020-16505-0.
[24] Tseng CT, Shrama E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012;7(8) https://doi.org/10.1371/journal.pone.0042942.
[25] Bolles M, Deming D, Long K, Agnihotram A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 2011;85(23):12201–9.
[26] Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng BH, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 2016;12:2351–6.
[27] Kim HW, Canchola JG, Brandt CD, Pyles G, Chanoock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated respiratory syncytial virus (RSV) vaccine. J Pediatr 1999;135:422–34.
[28] Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967;202:1075–80.
[29] Sekine T, Perez-Potti A, Rivera-Ballesteros D, Stralin K, Gorin JB, Olsson A, et al. Robust T-Cell Immunity in Convalescent Individuals with Atypical or Mild COVID-19. Cell 2020;183(1):158–68.
[30] Kwiasla S, Kimishiori JM, Josleym L, Jerke K, Ballantyne J, Royals M, et al. A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates. Curr Gene Ther 2014;14(3):200–10.
[31] Gaudinski MR, Houser KJ, Morabito KM, Hu Z, Yamshchukov G, Rothwell RS, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 2018;391(10120):552–62.
[32] Yadav PD, Kumar S, Agarwal K, Jain M, Patil DR, Mathial K, et al. Assessment of immunogenicity and protective efficacy of ZygcoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection. bioRxiv 2021.02.02.429480. https://doi.org/10.1101/2021.02.02.429480.
[33] Sheets RL, Stein J, Manetz T, Duffy C, Nason M, Andrews C, et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 2006;91:610–9.